Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for February 6, 2023. The press release will be issued at 4:30 a.m. PT and the call will begin at 5:00 a.m. PT (8:00 a.m. ET). The conference call can be accessed domestically at 866-952-8559 and internationally at 785-424-1743, using conference ID NBIX. A replay will be available approximately an hour after the event and archived for a month. Neurocrine focuses on developing treatments for neurological and endocrine disorders, with several FDA-approved therapies in its portfolio.

Positive

• Scheduled financial results release and conference call may indicate transparency and engagement with investors.
• Diverse portfolio includes FDA-approved treatments and 12 mid-to-late-stage clinical programs, suggesting potential growth.

Negative

• None.

Conference Call and Webcast Scheduled for Monday, February 6

SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on February 6, 2023.

The schedule for the press release and conference call / webcast is as follows:

• Q4 & Year-End 2022 Press Release:	February 6, 2023 at 4:30 a.m. PT / 7:30 a.m. ET
• Q4 & Year-End 2022 Conference Call:	February 6, 2023 at 5:00 a.m. PT / 8:00 a.m. ET
• Domestic Dial-In Number:	866-952-8559
• International Dial-In Number:	785-424-1743
• Conference ID:	NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, and 12 mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2022-financial-results-301723880.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences' Q4 and year-end 2022 financial results conference call?

The conference call is scheduled for February 6, 2023, at 5:00 a.m. PT (8:00 a.m. ET).

What is the domestic dial-in number for the Neurocrine Biosciences conference call?

The domestic dial-in number is 866-952-8559.

What can investors expect from the financial results announcement on February 6, 2023?

Investors can expect an update on the company's financial performance for Q4 and the entire year of 2022.

How can I access the webcast for Neurocrine Biosciences' financial results?

The webcast can be accessed on Neurocrine Biosciences' website under the Investors section.

What is the significance of Neurocrine Biosciences' diverse portfolio?

The diverse portfolio indicates potential for future growth and stability in revenue through multiple FDA-approved therapies.